✦ LIBER ✦

Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs

✍ Scribed by Beata Zahorowska; Philip J. Crowe; Jia-Lin Yang

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 469 KB
Volume: 135
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-009-0622-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EGFR-targeted therapies combined with ch

EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

✍ Peng Chen; Long Wang; Bing Liu; Hai-Zhong Zhang; Hong-Chen Liu; Zui Zou 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 225 KB

Perspectives of combined radioimmunother

Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer

✍ Frank B. van Gog; Ruud H. Brakenhoff; Marijke Stigter-van Walsum; Gordon B. Snow 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 119 KB 👁 2 views

Rhenium-186 based radioimmunotherapy (RIT) may have potential for the treatment of minimal residual disease in patients with squamous cell carcinoma of head and neck (HNSCC). In an effort to enhance the efficacy of RIT, we evaluated the combination of RIT and anti-epidermal growth factor receptor (E

Meropenem monotherapy versus combination

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients

✍ G. Behre; H. Link; G. Maschmeyer; P. Meyer; U. Paaz; M. Wilhelm; W. Hiddemann 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 189 KB

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 1 views

## Abstract The proteasome plays a pivotal role in the turnover of regulatory transduction proteins induced by activated cell membrane growth factor receptors. The epidermal growth factor receptor (EGFR) pathway is crucial in the development and progression of human epithelial cancers. Proteasome i

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 1 views

Downregulation of survivin and aurora A

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy

✍ Anat Biran; Michael Brownstein; Ronit Haklai; Yoel Kloog 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 892 KB

## Abstract Histone deacetylase (HDAC) inhibitors, such as valproic acid (VPA), constitute a novel class of anticancer agents that cause an increase in acetylated histones and thus restore the expression of dormant tumor‐suppressor and other genes related to cell differentiation, cell‐cycle arrest